Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Journal Pre-proof

2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors

Jianyuan Zhao, Guoning Zhang, Yongxin Zhang, Dongrong Yi, Quanjie Li, Ling Ma, SaiSai Guo, Xiaoyu Li, Fei Guo, Rongtuan Lin, Gia Luu, Zhenlong Liu, Yucheng Wang, Shan Cen

PII: S0166-3542(21)00199-6
DOI: https://doi.org/10.1016/j.antiviral.2021.105209
Reference: AVR 105209

To appear in: Antiviral Research

Received Date: 16 July 2021
Revised Date: 3 November 2021
Accepted Date: 15 November 2021

Please cite this article as: Zhao, J., Zhang, G., Zhang, Y., Yi, D., Li, Q., Ma, L., Guo, S., Li, X., Guo, F., Lin, R., Luu, G., Liu, Z., Wang, Y., Cen, S., 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors, Antiviral Research (2021), doi: https://doi.org/10.1016/j.antiviral.2021.105209.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier B.V.
2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors

Jianyuan Zhao†, Guoning Zhang†, Yongxin Zhang†, Dongrong Yi†, Quanjie Li†, Ling Ma†, SaiSai Guo†, Xiaoyu Li†, Fei Guo†, Rongtuan Lin‡, Gia Luu‡, Zhenlong Liu‡*, Yucheng Wang‡*, Shan Cen†*

1 Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China.
2 Institute of Pathogen Biology, Chinese Academy of Medical Science, Beijing, China.
3 Lady Davis Institute for Medical Research, McGill University and Jewish General Hospital, Montreal, Quebec, Canada.

*Correspondence: zhenlong.liu@mail.mcgill.ca (Z.L.), wangyucheng@imb.pumc.edu.cn (Y.W.) and shancen@imb.pumc.edu.cn (S.C.)

†These authors have contributed equally to this work and share first authorship
Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of Coronavirus Disease 2019 (COVID-19) pandemic. Despite intensive and global efforts to discover and develop novel antiviral therapies, only Remdesivir has been approved as a treatment for COVID-19. Therefore, effective antiviral therapeutics are still urgently needed to combat and halt the pandemic. Viral RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 demonstrates high potential as a reliable target for the development of antivirals. We previously developed a cell-based assay to assess the efficiency of compounds that target SARS-CoV-2 RdRp, as well as their tolerance to viral exoribonuclease-mediated proof-reading. In our previous study, we discovered that 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides specifically targets the RdRp of both respiratory syncytial virus (RSV) and influenza A virus. Thus, we hypothesize that 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides may also have the ability to inhibit SARS-CoV-2 replication by targeting its RdRp activity. In this research, we test a compound library containing 103 of 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides against SARS-CoV-2 RdRp, using our cell-based assay. Among these compounds, the top five candidates strongly inhibit SARS-CoV-2 RdRp activity while exhibiting low cytotoxicity and resistance to viral exoribonuclease. Compound 6-72-2a is the most promising candidate with the lowest EC₅₀ value of 1.41 μM and highest selectivity index (CC₅₀/EC₅₀) (above 70.92). Furthermore, our data suggests that 4-46b and 6-72-2a also inhibit the replication of HCoV-OC43 and HCoV-NL63 virus in a dose-dependent manner. Compounds 4-46b and 6-72-2a exhibit EC₅₀ values of 1.13 μM and 0.94 μM, respectively, on HCoV-OC43 viral replication. However, higher concentrations of these compounds are needed to effectively block HCoV-NL63 replication. Together, our findings successfully identified 4-46b and 6-72-2a as promising inhibitors against SARS-CoV-2 RdRp.

Key words: COVID-19, SARS-CoV-2, RdRp, nucleotide analog inhibitor, Remdesivir, 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides
INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to ravage the globe. As a highly prevalent threat to public health, it is responsible for more than 247.3 million infections and 5 million deaths worldwide [1]. Despite enormous vaccination campaigns across many continents, the lack of effective treatments and therapeutics contribute to massive global increases in the number of infections daily [1, 2]. In addition to the recently discovered SARS-CoV-2, six other human coronaviruses (HCoVs) have been previously identified: HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1 associate with mild symptoms and account for 15%–30% cases of common colds [3]. These four HCoVs are often used as tools for viral pathogenic studies and drug developments, most notably for the current COVID-19 pandemic. Particularly, the RdRp sequences are highly conserved across different CoVs, this is especially true for SARS-CoV-2 and HCoV-OC43 which belong in the same genus beta-coronavirus. Although several therapeutic agents such as Remdesivir have been approved as treatments by the FDA, no antiviral therapies so far have compelling evidence to be effective and the development of new antiviral agents remains imperative.

The SARS-CoV-2 genome ranges from 29.8 kb to 29.9 kb, and contains two open reading frames 1 (Orf1): Orf1a and Orf1b. Orf1b encodes 16 non-structural proteins (nsp1 to nsp16). Among them, the papain-like protease (nsp3), chymotrypsin-like main protease (3CL protease, nsp5), primase complex (nsp7–nsp8), RNA-dependent RNA polymerase RdRp (nsp12), helicase (nsp13), and exoribonuclease (nsp14) are crucial for SARS-CoV-2 replication [4-7]. As previously addressed, RdRp is one of the most promising targets for the development of antiviral therapies. Aside from playing a crucial role in viral RNA synthesis, RdRp lacks cellular homologues and is highly conserved in terms of sequence and structure among coronaviruses [8-12]. As previously shown, RdRp complex is comprised of catalytic subunit nsp12, two accessory subunits nsp7 and nsp8, and RNA template-product duplex [9, 13]. Nucleos(t)ide analogs (NAs) are potent RdRp inhibitors and restrict viral replication by incorporating into the nascent viral RNA, inducing the termination or reduction of RNA synthesis [4, 6]. However, the SARS-CoV-2 nsp14 exoribonuclease contributes to resistance of RdRp to NAs by excising erroneous nucleotides incorporated by nsp12 into viral RNA [14]. Thus, it is necessary to incorporate nsp14 in the screening system for RdRp inhibitors. An additional complication when using NAs is that these compounds must be metabolized to become 5'-triphosphate molecules after entering the host cell to be active [6, 15, 16]. To avoid the complex and time-consuming synthesis process of nucleoside triphosphate, we have built a cell-based assay using Gaussia-luciferase (Gluc) reporter to directly assess the capacity of NAs targeting SARS-CoV-2 RdRp without synthesizing the active nucleoside triphosphate form [12].

Currently, six RdRp inhibitors have been approved to use as antiviral drugs that includes 3 nucleos(t)ide analogues, Sofosbuvir, Remdesivir and Ribavirin; 1 nucleobase analog, Favipiravir and 2 nonnucleos(t)ide analogues, Beclabuvir (in combination with Asunaprevir and Daclatasvir) and Dasabuvir (in combination with ombitasvir/paritaprevir/ritonavir) (Figure 1A). In addition, other potential RdRp inhibitors exist, and these have been comprehensively summarized by Tian et al [17]. Many RdRp inhibitors have been repurposed...
for the COVID-19 pandemic, and at least 8 of them have shown significant anti-SARS-CoV-2 activity at the cellular level or in clinical trials (Figure 1B).

Our previous study has demonstrated that 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides target specifically RdRp of both respiratory syncytial virus (RSV) and influenza A virus, resulting into inhibition of viral replication at sub-micromolar EC$_{50}$ values with lower cytotoxicity comparing with ribavirin [18]. We hypothesize that the 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides could also inhibit SARS-CoV-2 through targeting its RdRp. Thus, a small-scale compound library containing mainly 2-((1H-indol-3-yl)thio)-N-phenyl-acetamide (Figure 2) was evaluated for the anti-SARS-CoV-2 activity. Using our cell-based Gluc assay, we identified several anti-SARS-CoV-2 candidates from this library. The five most effective candidates showed a dose-dependent inhibition of SARS-CoV-2 RdRp with EC$_{50}$ values ranging from 1.41 to 3.07 μM. Encouragingly, two of these candidates were efficient SARS-CoV-2 RdRp inhibitors, with activity levels close to Remdesivir. It is worth mentioning that there are only two compounds with a skeleton of 2-((indol-3-yl)thio)-N-benzyl-acetamides in the screened library and both of them were in the top 5 effective candidates. Thus, we have reported that a new series of 2-((indol-3-yl)thio)-N-benzyl-acetamides was synthesized and evaluated for its SARS-CoV-2 RdRp inhibitory effect and a more potent candidate against HCoV-OC43 than Remdesivir, recently [19].

![Figure 1. (A) Structures of FDA-approved antiviral agents targeting RdRp and (B) RdRp inhibitors repurposing for the COVID-19 pandemic](image-url)
Figure 2. The main compound skeletons in our RdRp targeting library and anti-SARS-CoV-2 candidates discovered

MATERIALS AND METHODS

1. Cells, transfection, and viruses

HEK293T, A549, and LLC-MK2 cells were cultured in Dulbecco’s modified Eagle's medium (DMEM; Gibco, Thermo Fisher Scientific, Waltham, MA, USA) with 10% (v/v) fetal bovine serum (FBS; Gibco). HCT-8 cells cultured in RPMI1640 medium with 10% FBS. Plasmids transfections were performed using Vigofect transfection reagents (Vigorous) according to the manufacturer’s instructions. HCoV-OC43 (VR-1558) was used to infect HCT-8 cells at an MOI of 0.1. The HCoV-NL63 strain Amsterdam I was used to infect LLC-MK2 cells at an MOI of 0.01.

2. Plasmids, compounds, and reagents

Codon-optimized pCOVID19-nsp12, pCOVID19-nsp7, pCOVID19-nsp8, pCOVID19-nsp10 and pCOVID19-nsp14 expression vectors encoded flag-tagged nsp12, nsp7, nsp8, nsp10 and nsp14 at their C-terminus, respectively. The plasmid pCoV-Gluc expressed the Gaussia-luciferase (Gluc) reporter gene flanked by 5’ and 3’ untranslated regions (UTRs) of SARS-COV-2 under the control of the CMV (cytomegalovirus) promoter. Briefly, 5’UTR-Gluc-3’UTR was first synthesized (Sangon Biotech) and then inserted into the BamHI and NotI sites of pRetroX-tight-Pur vector (kindly provided by Dr. Guo Fei) following amplification with the forward primers were for (5’-GGC GGA TCC ATT AAA GGT TTA TAC-3’) and reverse primed (5’-TTA GCG GCC GCG TCA TTC TCC TAA GAA-3’). Remdesivir (S8932) and Ribavirin (S2504) were obtained from Selleck chemicals (Houston, TX, USA) and dissolved in DMSO. A library of 103 2-((1H-indol-3-ylthio)-N-phenyl-acetamides derivatives was synthesized and a stock solution (10mM) was prepared in dimethyl sulfoxide (DMSO) (Table S1 in supplemental materials).

3. RNA isolation and Real-time RT-PCR

HEK293T cells were grown in DMEM containing 10% FBS for 24 hours before treatment with 5 μM or 10 μM Remdesivir or compounds for 24 hours. Total RNA was extracted with Aurum Total RNA mini kit. cDNA was synthesized using primer plus-Gluc-RT (5’-TGG ATC TTG CTG CGC AAT GT-3’) or minus-Gluc-RT (5’-ACT GTC GTT GAC AGG ACA CG-3’) for 1 hour at 37 °C. The cDNAs were quantified using Applied Biosystems QuantStudio (Thermo Fisher Scientific). Expression levels were normalized with GAPDH level. Primers Gluc Forward (5’-CGG GTG TGA CCG AAA GGT AA-3’) and Reverse (5’-TGG ATC TTG CTG GCG AAT GT-3’) were applied for PCR. GAPDH primers were Forward (5’-GTC CAC TGG CGT CTT CAC CA-3’) and reverse (5’-GTG GCA GTG ATG GCA TGG AC-3’).

4. Cell toxicity assay

Cell toxicity was measured in the water-soluble tetrazolium salt-8 (WST-8) reagent (CCK-8, Beyotime). Each compound was added to HEK293T cells at concentration ranging from 0.78
to 100 μM for 24-hour incubation. Then, 10 μL CCK-8 was added to each well for 1h incubation at 37 °C. The absorbance at 450 nm was measured using the Enspire 2300 Multiable reader (PekinElmer). The 50% cytotoxic concentration (CC50) was analyzed by comparing the viability of test compounds-treated cells and DMSO-treated cells.

5. Gluc activity assay

A stock of coelenterazine-h (Promega, Madison, WI, USA) was dissolved in absolute ethyl alcohol to a concentration of 1.022 mmol/L. Briefly, the stock was diluted in PBS to 16.7 μM and incubated in the dark for 30 min at room temperature. For the luminescence assay, 10μL of culture medium was added to each well of a 96-well plate and mixed with 60μL of 16.7 μM coelenterazine-h. Luminescence was measured during 0.5s using the Berthold Centro XS3 LB 960 microplate luminometer.

6. HCoV-OC43 and HCoV-NL63 cytopathic effects (CPE) assay

The anti-HCoV-OC43 and HCoV-NL63 activity was measured by the MTS Cell Proliferation Colorimetric assay kits (Promega, Madison, WI, USA). Briefly, HCT-8 cells and LLC-MK2 cells were infected with HCoV-OC43 (MOI=0.1) and HCoV-NL63 (MOI=0.01) respectively, with 2% FBS and each tested compound. Cells were then incubated at 33°C for 120 hours in 5% CO2 incubator. Subsequently, 20μL of MTS Cell Proliferation Colorimetric reagent was added into each well and cells were incubated for 3 hours at 37 °C in the presence of 5% CO2. Cell proliferation was measured at an absorbance at 490 nm using the Enspire 2300 Multiable reader (PekinElmer). HCT-8 cells or LLC-MK2 cells with virus infection but without drugs were used as negative controls to indicate 0 % CPE inhibition. The percentage CPE inhibition is shown in the Equation: The percentage CPE inhibition=(A490 of samples −A490 of negative control)/(A490 of positive control −A490 of negative control)×100.

7. Statistical analysis

Data are presented as the means ± SD from at least three independent experiments and the two-tailed t-test was used for statistical analysis. Differences between groups were considered statistically significant if p < 0.01(**), p < 0.001(***).

8. Synthesis

The 2-((1H-indol-3-yl)thio)-N-phenyl-acetamide and 2-((indol-3-yl)thio)-N-benzyl-acetamides were synthesized according to the process we reported early[19]. The 2,3-dithioindole were synthesized according to the scheme below (scheme 1). The 2-indolinone was substituted with phosphorus pentasulfide to introduce the first sulfur atom. The second sulfur atom at the 3-position was introduced by the substitution reaction of the indole ring by the Bunte
The diacid obtained by hydrolysis is coupled with the substituted aniline to obtain the product 4-43a and 4-43b, respectively.

**Scheme 1. Synthetic scheme for compounds 4-43a and 4-43b.** Reagents and conditions: (a) \( \text{P}_2\text{S}_5\), THF, reflux; (b) Ethyl 2-bromoacetate, potassium Carbonate, DMF; (c) Sodium \( S\)\((2\text{-ethoxy-2-oxoethyl})\) sulfurothioate, Iodine, DMSO, \(60^\circ\text{C}\); (d) \( \text{NaOH}, \text{EtOH/H}_2\text{O}\); (e) Substituted aniline, HATU, DIEA, dichloromethane.

**RESULTS:**

1. **Screening 2-\([(1\text{-indol-3-yl})\text{thio}]\)N-phenyl-acetamides through the CoV-RdRp-Gluc reporter assay**

In our previous study, we have developed a SARS-CoV-2 RdRp-dependent Gluc reporter system (CoV-RdRp-Gluc). It is a cell-based high-throughput screening assay for SARS-CoV-2 RdRp inhibitors based on the measurement of Gluc in culture medium. Briefly, the assay is based on a CMV promoter-driven reporter vector (CoV-Gluc) expressing the Gaussia-luciferase reporter gene flanked by 5' and 3' untranslated regions (UTRs) of SARS-CoV-2. Gluc RNA is subsequently amplified by SARS-CoV-2 RdRp (nsp12) in the presence of nsp7 and nsp8. Gluc activity thus correlates with the activity of SARS-CoV-2 RdRp (Figure 3A) [12]. The CoV-Gluc reporter vector and expression vectors of nsp12, nsp7 and nsp8 were transfected in HEK293T cells, which were exposed to various candidates 12 hours post transfection. After 24 hours incubation, Gluc activities were measured to evaluate the inhibitory potential of candidates toward SARS-CoV-2 RdRp. Initially, 103 2-\([(1\text{-indol-3-yl})\text{thio}]\)N-phenyl-acetamides were screened through our CoV-RdRp-Gluc reporter assay. As shown in Supplementary Table S1, all 2-\([(1\text{-indol-3-yl})\text{thio}]\)N-acetamides (\( R1=R2=\text{H} \)) showed a inhibition toward RdRp activity except for 4-53c and 4-53d. 2-\([(1\text{-indol-3-yl})\text{thio}]\)N-\((\text{bromophenyl})\)acetamide (\( R3=\text{bromoaniline} \)) (1-HB-9 and 1-HB-10) showed the strongest inhibitory potential in the acetanilide. When aniline was substituted with benzylamine in R3, their inhibitory activity was significantly enhanced (4-46b, 4-48 vs. 1-HB-3, 1-HB-5). After the introduction of a methoxy group, a chlorine atom or a 5- bromine atom to the benzene ring in indole, a 2-15 folds increase in inhibitory potential was observed. A methyl- or a tert-butoxycarbonyl- substitution in R2 was also beneficial to the inhibitory activity. When sulfide was oxidized to sulfoxide or sulfone, no significant changes in RdRp inhibition was noted.
When a similar substitution was introduced to the 2,3-position on indole, RdRp inhibition was improved in comparison to compounds with a single 3-position substitution (4-43a and 4-43b). Importantly, 19 candidates repressed SARS-CoV-2 RdRp activity more than 50% at a 10 μM concentration and the top five of them shown as blue spot in Figure 3B can markedly repress SARS-CoV-2 RdRp activity at around 80% at 10 μM (P<0.005). Among them, 6-72-2a surprisingly showed similar inhibition effect as Remdesivir (Table S1). The lipophilic Boc-group may contribute to the activity and a similar result was discovered in our another research, in which the stability of the Boc-group was also demonstrated [20]. The structures of these five compounds also suggest that chemical structure of 2-((1H-indol-3-yl)thio)-acetamide is pivotal element for its capability against RdRp (Figure 3C).

Figure 3. Inhibition of SARS-CoV-2 RdRp by 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides. (A) Schematic of the CoV-RdRp-Gluc reporter assay. (B) Overview of the results from the CoV-RdRp-Gluc reporter assay. (C) Chemical
structure of top five compounds. (D-I) Dose-response curves (EC$_{50}$/CC$_{50}$) for top five compounds. HEK293T cells were transfected with CoV-Gluc, nsp12, nsp7, and nsp8 expression vector at a ratio of 1:10:30:30. Twelve hours post transfection, cells were re-seeded in 96-well plates (10$^4$/well) and treated with serially dilution of compounds 4-43b (D), 4-46a (E), 4-46b (F), 6-72-1b (G), 6-72-2a (H) and Remdesivir (I). Gluc activity was measured in harvested medium after 24 hours incubation. CC$_{50}$ values were measured in HEK293T cells with CCK-8 kits. (J) The EC$_{50}$ of active compounds against SARS-CoV-2 RdRp in A549 cells. A549 cells (5$x10^4$) were co-transfected with the indicated plasmids (50ng, 200ng, 600ng and 600ng for pCoV-Gluc, nsp12, nsp7 and nsp8, respectively). Twelve hours post transfection, cells were re-seeded in 96-well plates (10$^4$/well) and treated with serially dilution of compounds indicated above. Gluc activity was measured after 72 hours incubation. (K) CC$_{50}$ values of the active compounds were measured in A549 cells with CCK-8 kits. (D-K) Results shown are the average of three independent experiments. Error bars indicate SD.

2. Evaluation of anti-SARS-CoV-2 RdRp activity of top five compounds

To evaluate the inhibition of the five most effective candidates against SARS-CoV-2 RdRp, EC$_{50}$ and CC$_{50}$ were evaluated for each compound with increasing doses. All top five compounds showed a dose-dependent inhibition of SARS-CoV-2 RdRp activity (Figure 3D-I). Compound 6-72-2a represented the most promising compound showing the lowest EC$_{50}$ value (1.41 μM) with the highest selectivity index (CC$_{50}$/EC$_{50}$) (above 70.92) (Figure 3H). Compound 4-46b also showed a strong SARS-CoV-2 RdRp inhibition effect with an EC$_{50}$ value of 1.70 μM and CC$_{50}$ value of 75.52 μM (Figure 3F). EC$_{50}$ values of other tested compounds 4-43b, 4-46a, and 6-72-1b were 3.07 μM, 2.75 μM and 2.53 μM, respectively (Figure 3D, 3E, and 3G). Next, we evaluated the inhibition of 4-46b and 6-72-2a with the cell-based assay in A549 cell line. Surprisingly, SARS-CoV-2 RdRp activity was restrained by 4-46b and 6-72-2a, presenting low EC$_{50}$ value of 1.58 μM and 1.18 μM, respectively, which is close to the EC$_{50}$ of Remdesivir 0.73 μM (Figure 3J). The CC$_{50}$ values of 4-46b and 6-72-2a in A549 cells were 76.25 μM and above 100 μM respectively, which were much higher than their EC$_{50}$ values (Figure 3K). Together, these data support that 4-46b and 6-72-2a were determined as promising inhibitors against SARS-CoV-2 RdRp. Moreover, we have measured the effect of the active compounds 4-43b, 4-46a, 4-46b, 6-72-1b and 6-72-2a on the expression of the Gluc reporter plasmid in the absence of viral RdRp. Briefly, HEK293T cells were co-transfected with a pCoV-Gluc plasmid and incubated with the active compounds indicated above, respectively. Then levels of Gluc were determined. The results shown that these compounds have no significant impact on the expression of Gluc in the absence of SARS-CoV-2 RdRp even at a higher concentration of 10 μM (Figure S1). This suggests that these compounds target the replication of RNA driven by viral RdRp.

3. Reducing the RNA synthesis efficiency of SARS-CoV-2 RdRp by top five compounds

To further confirm the inhibition activity of the selected compounds against SARS-CoV-2 RdRp, RNA synthesis mediated by SARS-CoV-2 RdRp was examined by quantification of the levels of plus-strand and minus-strand RNA of Gluc following treatment with 5 μM and 10 μM of each compound. Compounds diminished the levels of both plus-strand and minus-strand Gluc RNA in a dose-dependent manner (Figure 4A-E). Compound 6-72-2a reduced both plus-strand and minus-strand RNA levels of controls about 80% at 10 μM, an efficiency comparable to that of our positive control, Remdesivir (Figure 4F).
4. The tolerance of top five compounds to SARS-CoV-2 exoribonuclease activity

The exoribonuclease nsp14 and its activator nsp10 play an important proofreading function as SARS-CoV-2 replicates. This contributes SARS-CoV-2 RdRp resistant to NA inhibitors, such as ribavirin [21, 22]. Thus, the inhibitory potential of selected compounds was evaluated in the presence of nsp14 /nsp10. The CoV-Gluc report vector and the expression vectors of nsp12, nsp7, nsp8, nsp10 and nsp14 were transfected in HEK293T cells, followed by treatment with different dilution of the compounds. As we previously demonstrated, nsp14/nsp10 lead to the inappreciable decrease of Gluc activity[12]. Our results illustrated that all compounds, i.e. 4-43b, 4-46a, 4-46b, 6-72-1b and 6-72-2a showed strong tolerance to the presence of nps14/nsp10 with EC\textsubscript{50} value of 3.62 μM, 2.89 μM, 2.52 μM, 2.56 μM, 1.70 μM, respectively (Figure 5A-E). In fact, all compounds presented an inhibitory potential very similar to the activity observed against nsp12 only (ratio 12+14/12 were all close to 1). Results obtained with Remdesivir, showed resistance to proofreading activity (EC\textsubscript{50} value of 2.03 μM; ratio 12+14/12 of 1.93) (Figure 5F and Table 1). However, the nps14/nsp10 markedly increased the EC\textsubscript{50} value of compound Ribavirin (the ratio 12+14/12 is above 9.18) (Figure 5G and Table 1). Together, these five compounds were identified as specific SARS-CoV-2 RdRp inhibitors, among them, 4-46b and 6-72-2a present the strongest inhibition activity against SARS-CoV-2 RdRp.
Figure 5. The top five compounds were resistant to SARS-CoV-2 exoribonuclease. HEK293T cells were transfected with CoV-Gluc, nsp12, nsp7, nsp10 and nsp14 plasmid DNA at the ratio of 1:10:30:30:25:25. Twelve hours post transfection, cells were re-seeded in 96-well plates (10^4/well) and treated with serially diluted compounds 4-43b (A), 4-46a (B), 4-46b (C), 6-72-b1 (D), 6-72-2a (E), Remdesivir (F) and Ribavirin (G). After 24 hours, Gluc activity in supernatants were quantified. Results shown are the average of three independent experiments. Error bars indicate SD.

Table1. Summary of top five compounds toward SARS-CoV-2 RdRp and anti-Coronavirus activity

| Compound          | HEK293T | A549 |
|-------------------|---------|------|
|                   | Nsp12 (EC_{50}/μM) | CC_{50}/μM | Nsp12 (EC_{50}/μM) | CC_{50}/μM | Nsp12 (EC_{50}/μM) | CC_{50}/μM | Anti-HCoV-OC43 (EC_{50}/μM) | Anti-HCoV-NL63 (EC_{50}/μM) |
| 4-43b             | 3.07    | 96.19 | 31.33 | 3.62 | 1.18 |
| 4-46a             | 2.75    | 84.22 | 30.63 | 2.89 | 1.05 |
| 4-46b             | 1.70    | 75.52 | 44.42 | 2.52 | 1.48 | 1.58 | 76.23 | 1.13 | >50 |
| 6-72-b1           | 2.53    | 93.53 | 36.97 | 2.56 | 1.01 |
| 6-72-2a           | 1.41    | >100  | >70.92 | 1.70 | 1.21 | 1.18 | >100 | 0.94 | 12.5 |
| Remdesivir        | 1.05    | >100  | >95.24 | 2.03 | 1.93 | 0.73 | 0.82 | 2.89 |
| Ribavirin         | 108.8   | >1000 | >9.18 | 0.69 | 2.13 |
| 4-46b & Remdesivir|         |       |       | 6.00 | 1.68 |
| 6-72-2a & Remdesivir|    |       |       | 6.00 | 1.68 |

5. Assessment of anti-HCoVs activity of compounds 4-46b and 6-72-2a

As HCoV-OC43 and HCoV-NL63 are human coronaviruses are commonly used in preclinical antiviral drug development. Besides, the RdRp sequences are highly conserved across
different CoVs and both SARS CoV-2 and HCoV-OC43 are betacoronavirus. Herein, in this cell-based assay, both HCT-8 and LLC-MK2 cell lines were infected with HCoV-OC43 and HCoV-NL63 respectively, followed by measuring the CoV-induced cytopathic effect (CPE) inhibition as an output[23]. Briefly, HCT-8 or LLC-MK2 cells were pretreated with serial dilution of 4-46b and 6-72-2a for 48h, and subsequently infected with HCoV-OC43 and HCoV-NL63, respectively (Figure 6). Additionally, we also measured the CC_{50} of the compounds 4-46b and 6-72-2a in HCT-8 and LLC-Mk2 cells. The results showed that the CC_{50} values of 4-46b and 6-72-2a were higher than the highest concentrations of the HCoV-OC43 and HCoV-NL63 cytopathic effects (CPE) assay both in HCT-8 and LLC-MK2 cells (Figure 6 E-F). Results demonstrated that both compounds 4-46b and 6-72-2a effectively inhibited HCoV-OC43 and HCoV-NL63 replication in a dose-dependent manner. HCoV-OC43 viral replication demonstrated EC_{50} values of 1.13 μM and 0.94 μM for compounds 4-46b and 6-72-2a, while higher concentrations of these compounds were needed to effectively block HCoV-NL63 replication. However, the EC_{50} values for HCoV-OC43 by the combining of active compounds 4-46b and 6-72-2a with Remdesivir are 0.69 μM and 0.60 μM, respectively; for HCoV-NL63 by combining of 4-46b and 6-72-2a with Remdesivir are 2.13 μM and 1.68 μM, respectively. This suggests that EC_{50} values for HCoV-OC43 and HCoV-NL63 can be reduced by combining these agents with Remdesivir to achieve synergy.
Figure 6. The anti-HCoV-OC43 and anti-HCoV-NL63 activities of 4-46b and 6-72-2a. HCT-8 and LLC-MK2 cells were seeded in 96-wells for 48h, and then infected with HCoV-OC43 (MOI=0.1) and HCoV-NL63 (MOI=0.01) respectively, and subsequently treated with serial dilutions of 4-46b (A and C) or 6-72-2a (B and D) 1-hour post-infection. After a 120-hour infection, 20 μL of MTS Cell Proliferation Colorimetric reagent was added into each well and cells were incubated for 3 hours at 37 °C. Optical density at 490nm wavelength was measured. (E-F) CC_{50} values of the active compounds were measured in HCT-8 and LLK-MK2 cells with CCK-8 kits. Results shown are the average of three independent experiments. Error bars indicate SD.

CONCLUSION:
To contribute to the ongoing COVID-19 pandemic, intensive efforts in the development of antiviral drugs are still needed. Viral RdRp is one of most valuable targets against SARS-CoV-2. As our previously reported, we developed a CoV-RdRp-Gluc reporter assay and demonstrated that 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides could inhibit RSV and IAV RdRp activity. In this study, we tested 103 2-((1H-indol-3-yl)thio)-N-phenyl-acetamide candidates using an adapted CoV-RdRp-Gluc reporter assay. Five of these compounds effectively inhibited SARS-CoV-2 RdRp and two of them were most effective inhibitors of HCoV-OC43 and HCoV-NL63 replication.
AUTHOR CONTRIBUTION

SC, YW and ZL conceived the idea of project. JZ, GZ and YZ performed the experiments. DY and QL helped with the resources. LM and SG contributed to validation. ZL drafted the manuscript. XL, FG, RL, GL and SC reviewed and edited the manuscript. All the authors have read and approved the manuscript for submission.

ACKNOWLEDGMENTS

We appreciate the support of following funds: the National Mega-Project for Infectious Disease [2018ZX10301408], the National Mega-Project for Significant new drug discovery [2018ZX09711003-002-002], the National Key Research and Development program of China [2018YFE0107600 and 2016YFD0500307], CAMS Innovation Fund for Medical Sciences [2018-I2M-3-004 and 2020-I2M-2-010], and the Fundamental Research Funds for the Central Universities [33320200046]. The National Infrastructure of Microbial Resources [NIMR-2014-3] and CAMS Collection Center of Pathogenic Micro-organisms [CAMS-CCPM-A] also provide valuable reagents.

NOTES

The authors declare no competing financial interest.

SUPPLEMENTARY MATERIAL

Supplementary Table1 Structure-activity relationship analysis of 103 anti-SARS-CoV-2 RdRp hits

Supplementary data1 NMR and MS data for 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides

Supplementary data2 NMR spectra of top 5 compounds 4-43b, 4-46a, 4-46b, 6-72-1b, and 6-72-2a

Supplementary data3 NMR spectra of other active compounds

Supplementary FigureS1 Effects of compound 4-43b, 4-46a, 4-46b, 6-72-1b and 6-72-2a on Gluc expression

REFERENCE:

1. (JHU), C.f.S.S.a.E.C.a.J.H.U., https://coronavirus.jhu.edu/map.html. 2020.
2. Beigel, J.H., et al., Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med, 2020. 383(19): p. 1813-1826.
3. Malik, Y.A., Properties of Coronavirus and SARS-CoV-2. Malays J Pathol, 2020. 42(1): p. 3-11.
4. Zhu, W., et al., RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery. SLAS Discov, 2020. 25(10): p. 1141-1151.
5. Jiang, Y., W. Yin, and H.E. Xu, RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19. Biochem Biophys Res Commun, 2021. 538: p. 47-53.
6. Shannon, A., et al., Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Antiviral Res, 2020. 178: p. 104793.
7. Shuhui Song, L.M., Dong Zou, Dongmei Tian, Cuiping Li, Junwei Zhu, Meili Chen, Anke Wang, Yingke Ma, Mengwei Li, Xuefei Teng, Ying Cui, Guangya Duan, Mochen Zhang, Tong Jin, Chengmin Shi, Zhenglin Du, Yadong Zhang, Chuandong Liu, Ruijiao Li, Jingyao Zeng, Lili Hao, Shuai Jiang, Hua Chen, Dali Han, Jingfa Xiao, Zhang Zhang, Wenming Zhao, Yongbiao Xue, Yiming Bao, The global landscape of SARS-CoV-2 genomes, variants, and haplotypes in 2019nCoVR. Biorxiv, 2020.
8. Chien, M., et al., Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19. J Proteome Res, 2020.
9. Hillen, H.S., et al., Structure of replicating SARS-CoV-2 polymerase. Nature, 2020.
10. Aftab, S.O., et al., Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach. J Transl Med, 2020. 18(1): p. 275.
11. Shyr, Z.A., et al., Drug Discovery Strategies for SARS-CoV-2. J Pharmacol Exp Ther, 2020. 375(1): p. 127-138.
12. Zhao, J., et al., A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase. Antiviral Res, 2021. 190: p. 105078.
13. Gao, Y., et al., Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science, 2020. 368(6492): p. 779-782.
14. Smith, E.C., et al., Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog, 2013. 9(8): p. e1003565.
15. Jockusch, S., et al., A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19. Antiviral Res, 2020. 180: p. 104857.
16. Wang, Q., et al., Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase. Cell, 2020. 182(2): p. 417-428 e13.
17. Tian, L., et al., RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic. Eur J Med Chem, 2021. 213: p. 113201.
18. Zhang, G.N., et al., Design and synthesis of 2-((1H-indol-3-yl)thio)-N-phenylacetamides as novel dual inhibitors of respiratory syncytial virus and influenza virus A. Eur J Med Chem, 2020. 186: p. 111861.
19. Zhang, G.N., et al., Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors. Eur J Med Chem, 2021. 223: p. 113622.
20. Zhao, J., et al., Quinoline and Quinazoline Derivatives Inhibit Viral RNA Synthesis by SARS-CoV-2 RdRp. ACS Infect Dis, 2021. 7(6): p. 1535-1544.
21. Ma, Y., et al., Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex. Proc Natl Acad Sci U S A, 2015. 112(30): p. 9436-41.
22. Ferron, F., et al., Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proc Natl Acad Sci U S A, 2018. 115(2): p. E162-E171.

23. Li, Q., et al., Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase. Acta Pharm Sin B, 2021.
Dear editor,

Here we declare that there is no conflict of interest regarding this submission.

Best regards,

Zhenlong Liu, Ph. D

McGill University, Canada

Email: Zhenlong.liu@mail.mcgill.ca

Leading correspondence:

Pro. Shan Cen

Chinese Academy of Medical Sciences & Peking Union Medical College Institute of Medicinal Biotechnology, Beijing, China

Email: shancen@imb.pumc.edu.cn